Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.60 |
| ▸ | EGFR | P00533 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1463877 | 0.92 | EGFR (0.55) | CYP3A4EGFRKMT2AKDM4EHTT | |
| SCHEMBL1464587 | 0.86 | EGFR (0.67) | CYP3A4EGFRKMT2AKDM4EHTT | |
| SCHEMBL1463978 | 0.82 | KCNH2 (0.60) | CYP3A4KMT2AKDM4EMEN1POLB | |
| SCHEMBL8922268 | 0.80 | CYP3A4 (0.49) | CYP3A4EGFRKMT2AKDM4EHTT | |
| SCHEMBL14161046 | 0.80 | ADRA1A (0.55) | KMT2AKDM4ESMN1; SMN2MEN1POLB | |
| SCHEMBL7770758 | 0.79 | CYP3A4 (0.48) | CYP3A4EGFRKMT2AKDM4EHTT | |
| SCHEMBL1463838 | 0.79 | KCNH2 (0.60) | CYP3A4EGFRKDM4ERXFP1POLB | |
| SCHEMBL8845824 | 0.78 | KMT2A (0.57) | CYP3A4EGFRKMT2AMEN1RXFP1 | |
| SCHEMBL27926165 | 0.77 | ALDH1A1 (0.60) | KMT2AKDM4ESMN1; SMN2MEN1RXFP1 | |
| SCHEMBL31276870 | 0.76 | KDM4E (0.70) | EGFRKMT2AKDM4EHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071148-A1 | COMPOUNDS AS THE ESTROGEN RELATED RECEPTORS MODULATORS AND THE USES THEREOF | GUANGZHOU INSTITUTE OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2011-03-24 | — | — | US | claimed |
| US-20110071148-A1 | COMPOUNDS AS THE ESTROGEN RELATED RECEPTORS MODULATORS AND THE USES THEREOF | GUANGZHOU INSTITUTE OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2011-03-24 | — | — | US | disclosed |
| EP-2266962-A1 | THE COMPOUNDS AS THE ESTROGEN RELATED RECEPTORS MODULATORS AND THE USES THEREOF | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences (CN) | 2010-12-29 | — | — | EP | disclosed |
| CN-101531638-A | Compounds useful as estrogen-related receptor modulators and uses thereof | CHINESE ACADEMY OF SCIENCES GU | 2009-09-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071148-A1 | COMPOUNDS AS THE ESTROGEN RELATED RECEPTORS MODULATORS AND THE USES THEREOF | ESRRA, ESRRB, ESRRG | CYP3A4 142/4885EGFR 144/4885KMT2A 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.